Hepatocellular carcinoma: new developments
P Ganesan, LM Kulik - Clinics in liver disease, 2023 - liver.theclinics.com
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide and a leading cause of death in cirrhosis. The prognosis in HCC is poor, with …
worldwide and a leading cause of death in cirrhosis. The prognosis in HCC is poor, with …
Combination immunotherapy for hepatocellular carcinoma
L Rimassa, RS Finn, B Sangro - Journal of Hepatology, 2023 - Elsevier
Single-agent immune checkpoint inhibitors (ICIs) have been tested in patients with
advanced hepatocellular carcinoma (HCC), leading to objective response rates of 15-20 …
advanced hepatocellular carcinoma (HCC), leading to objective response rates of 15-20 …
Critical appraisal of guideline recommendations on systemic therapies for advanced hepatocellular carcinoma: a review
S Cappuyns, V Corbett, M Yarchoan, RS Finn… - JAMA …, 2024 - jamanetwork.com
Importance The combination of immune checkpoint inhibitors with antiangiogenic agents
has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC) …
has revolutionized the treatment landscape of advanced hepatocellular carcinoma (HCC) …
TKIs in combination with immunotherapy for hepatocellular carcinoma
B Stefanini, L Ielasi, R Chen, C Abbati… - Expert review of …, 2023 - Taylor & Francis
Introduction The treatment landscape of hepatocellular carcinoma (HCC) has significantly
changed over the last 5 years with multiple options in the frontline, second line, and beyond …
changed over the last 5 years with multiple options in the frontline, second line, and beyond …
AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis
This Practice Guidance from the American Association for the Study of Liver Disease
(AASLD) intends to coalesce best practice recommendations for the identification of portal …
(AASLD) intends to coalesce best practice recommendations for the identification of portal …
[HTML][HTML] Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Background IMbrave150 has established the superiority of atezolizumab plus bevacizumab
over sorafenib in patients with unresectable hepatocellular carcinoma (HCC). Methods We …
over sorafenib in patients with unresectable hepatocellular carcinoma (HCC). Methods We …
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Systemic therapy for advanced hepatocellular carcinoma has expanded at an
unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the …
unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the …
Immune checkpoint inhibitors for child-pugh class B advanced hepatocellular carcinoma: a systematic review and meta-analysis
Importance Immune checkpoint inhibitors (ICIs) are increasingly used in patients with
advanced hepatocellular carcinoma (HCC). However, data on ICI therapy in patients with …
advanced hepatocellular carcinoma (HCC). However, data on ICI therapy in patients with …
Updates on systemic therapy for hepatocellular carcinoma
P Ntellas, I Chau - American Society of Clinical Oncology Educational …, 2024 - ascopubs.org
This review explores the dynamic landscape of hepatocellular carcinoma (HCC) treatment,
emphasizing on recent developments across various stages and therapeutic approaches …
emphasizing on recent developments across various stages and therapeutic approaches …
Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Background Atezolizumab-bevacizumab (atezo-bev) is recommended as first-line therapy
for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness …
for patients with unresectable hepatocellular carcinoma (uHCC). However, its effectiveness …